Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 24.65M | 25.32M | 24.74M | 24.62M | 24.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.65M | 25.32M | 24.74M | 24.62M | 24.75M |
| Cost of Revenue | 9.00M | 9.39M | 8.60M | 8.49M | 9.96M |
| Gross Profit | 15.65M | 15.93M | 16.14M | 16.13M | 14.79M |
| SG&A Expenses | 10.59M | 11.22M | 11.92M | 12.17M | 12.17M |
| Depreciation & Amortization | 2.46M | 2.42M | 2.43M | 2.43M | 2.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.00M | 23.65M | 23.09M | 23.77M | 25.04M |
| Operating Income | 1.66M | 1.68M | 1.65M | 850.00K | -290.00K |
| Income Before Tax | -3.01M | 446.00K | -327.00K | 615.00K | -759.00K |
| Income Tax Expenses | -333.00K | 366.00K | -12.00K | 99.00K | -206.00K |
| Earnings from Continuing Operations | -2.68M | 80.00K | -315.00K | 516.00K | -553.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.68M | 80.00K | -315.00K | 516.00K | -553.00K |
| EBIT | 1.66M | 1.68M | 1.65M | 850.00K | -290.00K |
| EBITDA | 3.94M | 4.10M | 4.08M | 3.28M | 1.99M |
| EPS Basic | -0.08 | 0.00 | -0.01 | 0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.01 | 0.00 | 0.00 | -0.05 |
| EPS Diluted | -0.08 | 0.00 | -0.01 | 0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.01 | 0.00 | 0.00 | -0.05 |
| Average Basic Shares Outstanding | 32.29M | 32.43M | 32.29M | 32.26M | 29.60M |
| Average Diluted Shares Outstanding | 32.29M | 32.43M | 32.29M | 32.26M | 29.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |